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Artiﬁcial chromosomes and minichromosome-like episomes are large DNA molecules capable of containing whole genomic loci,
and be maintained as nonintegrating, replicating molecules in proliferating human somatic cells. Authentic human artiﬁcial
chromosomes are very diﬃcult to engineer because of the diﬃculties associated with centromere structure, so they are not widely
used for gene-therapy applications. However, OriP/EBNA1-based episomes, which they lack true centromeres, can be maintained
stably in dividing cells as they bind to mitotic chromosomes and segregate into daughter cells. These episomes are more easily
engineered than true human artiﬁcial chromosomes and can carry entire genes along with all their regulatory sequences. Thus,
these constructs may facilitate the long-term persistence and physiological regulation of the expression of therapeutic genes, which
iscrucialforsomegenetherapyapplications.Inparticular,theyarepromisingvectorsforgenetherapyininheriteddiseasesthatare
caused by recessive mutations, for example haemophilia A and Friedreich’s ataxia. Interestingly, the episome carrying the frataxin
gene (deﬁcient in Friedreich’s ataxia) has been demonstrated to rescue the susceptibility to oxidative stress which is typical of
ﬁbroblasts from Friedreich’s ataxia patients. This provides evidence of their potential to treat genetic diseases linked to recessive
mutations through gene therapy.
1. The Rationale behindthe Use of
Large DNA Molecules in Gene Therapy
Gene therapy is deﬁned as the transfer of nucleic acid
molecules (usually DNA) to a patients somatic cells in
order to prevent, treat, or alleviate a speciﬁc condition.
Diﬀerent gene therapy strategies have been designed to suit
diﬀerent types of diseases, the most “classical” of which
involves gene delivery to target cells in order to obtain
optimal expression of the gene introduced. This therapeutic
approachisparticularlywellsuitedforinheriteddiseasesthat
are caused by recessive mutations, since these are typically
associated with the absence of a functional gene product or
the drastic decrease in the expression of a gene. In these
cases, the “therapeutic gene” must be inserted within a DNA
molecule (usually a bacterial plasmid) along with all its
essential regulatory sequences in order to ensure the correct
expression of the gene in the target cells. To facilitate the
adequate cellular uptake of DNA molecules, they must be
packed within appropriate “gene delivery vehicles”.
Viral vectors have become the preferred “gene delivery
vehicles” in the ﬁeld of gene therapy due to their extremely
high eﬃciency of gene transfer in somatic cells. However,
viralvectorsfailtofulﬁlalltherequirementsforan“optimal”
gene therapy vector. Ideally, the best gene therapy protocol
would involve a single administration of the therapeutic
gene to the organism, such that it could replicate and seg-
regate alongside the endogenous chromosomes, if necessary,
thereby permitting long-term maintenance in any dividing
cell. However, most viral vectors are either nonintegrating
episomes that are unable to replicate, segregate, and persist
in dividing cells, or they are integrating vectors. These latter2 Journal of Biomedicine and Biotechnology
vectors insert into the chromosomes of the host cell, and
although they can therefore persist in proliferating cells, they
carry the risk of producing insertional mutagenesis.
Adenoviruses are DNA viruses that have a linear double-
stranded 36 kb genome. These viruses can be used as
nonintegrating vectors since their genome is maintained as
anepisomeonceitisreleasedintothenucleusofthehostcell.
However, these episomes are lost after several cell divisions.
Moreover, the ﬁrst-generation adenoviral vectors elicited
a strong immune response that led to elimination of the
transduced cells, and the humoral response excluded them
after future administrations [1, 2]. To diminish or overcome
this reaction, multiple deletions have been introduced into
the subsequent generations of high-capacity [3] “gutless”
adenoviral vectors [4, 5]. Nevertheless, while these vectors
can now infect a wide range of cells, their lack of persistence
in dividing cells represents an important weakness.
Retroviral-based vectors are capable of transducing a
wide variety of dividing cells and they are eﬃciently inte-
grated in the genome of the host cells [6]. However, this
lattercharacteristic representstheir major disadvantagesince
random integration may cause insertional mutagenesis, and
the ensuing activation and/or silencing of undesirable genes
mighteventriggeroncogenictransformationinthehostcells
[7, 8]. Indeed, some patients treated with retroviral vectors
in a clinical trial for severe combined immunodeﬁciency
(SCID) developed leukemia as a consequence of vector
integration [9].
While Lentiviruses belong to the retrovirus family,
they are able to transduce both proliferating and non-
proliferating cells, augmenting the range of target cells [10,
11]. These viruses are currently the most widely used gene
therapy vectors, as they sometimes permit prolonged gene
expression, although gradually silencing of gene expression
has also been reported on occasion [12].
Finally, most viral vectors have a limited packaging
capacity and they cannot accommodate large genes. For
this reason, most constructs used for gene therapy are
“minigenes”, consisting of cDNA sequences (instead of entire
genes) under the control of heterologous promoters (usually
small compacted promoter sequences of viral origin). These
“minigene constructs” often exhibit variable expression
or lack tissue speciﬁcity, and they may not be properly
regulated in somatic cells, being completely “silenced” in
many cases, which obviously restricts their usefulness in
gene therapy. Indeed, studies performed in transgenic mice
have demonstrated that these “minigene constructs” are very
susceptible to being switched oﬀ by neighbouring chromatin
[13]. On the other hand, there are cases where the cDNA is
too big to be contained in one of these vector systems and
some “nonessential” regions have to be eliminated [14].
By contrast, studies performed in transgenic mice have
highlighted the advantages of using large fragments of
genomic DNA that permit the delivery of intact mammalian
genes with all their introns, promoters, enhancers, and
long-range controlling elements. By using gene’s normal
promoter and controlling elements, the level and control of
expression is comparable to the endogenous expression of
the gene. The experience gained from using yeast artiﬁcial
chromosomes (YACs) and bacterial artiﬁcial chromosomes
(BACs) has shown that large genomic fragments drive
tissue-speciﬁc expression at endogenous levels [15–20]. For
example, transgenic mice carrying the intact human cystic
ﬁbrosis transmembrane regulator gene (CFTR), which spans
200kb of a 300kb YAC [21], express CFTR in an appropriate
tissue speciﬁc manner and complement the cftr defect in null
mice.Similarphysiologicalexpressionhasalsobeenachieved
with the Huntingtin gene, which has been diﬃcult to express
from minigene constructs [22]. Likewise, the use of a YAC
or BAC carrying the entire frataxin gene has rescued frataxin
knock-out mice from embryonic lethality [16, 19]. In view of
thesedata,largeDNAmoleculesseemtobebettercandidates
as vectors for gene therapy than the typical viral vectors, with
their limited capacity.
A sar e s u l to ft h eh u m a ng e n o m ep r o j e c t ,B A C sa r e
availablethatcoverthewholegenome.Giventhattheaverage
size of a BAC is approximately 150kb, most genes, together
with all their regulatory elements, can be included in such
a construction. A system for linking overlapping BACs by
homologous recombination in E. coli has been described for
when a BAC containing a whole locus is not available, or
if new regions need to be added upstream or downstream
of a given gene within a BAC [23–25]. Also recombination
has been used to modify BACs with diﬀerent tags, which
is very useful in studies of protein-protein or DNA-protein
interactions, and of protein localization [26].
This paper will deal with mammalian artiﬁcial chromo-
somesandminichromosome-likeepisomes.Wewillfocuson
recent advances on the use of BACs containing genomic loci
as a platform for the design of artiﬁcial minichromosome-
like vectors for gene therapy applications, and on the
“delivery vehicles” that can accommodate such large DNA
molecules. We will also analyse two examples of applications
of these artiﬁcial minichromosome-like vectors for rare
genetic diseases (haemophilia A and Friedreich’s ataxia).
2. Mammalian ArtiﬁcialChromosomes
An obvious vector to stably carry large genomic DNA
fragments would be an artiﬁcial minichromosome that
must have a replication origin and a centromere, enabling
the DNA molecule to replicate during S phase and to
correctly segregate during mitosis. In addition, if the DNA
molecule is lineal telomeres must be present at both ends to
guarantee its stability. The centromere is the most important
chromosomal element since it is crucial for the attachment
of chromosomes to the mitotic spindle and their correct
segregation in mitosis. Centromeric DNA binds the CENP
proteins that form the scaﬀold for the kinetochore, the
structure connecting the centromere to the spindle micro-
tubules. Artiﬁcial chromosomes have been built in yeast
without any diﬃculty, since yeast chromosomes contain
small centromeres. However, mammalian centromeres are
very large and extraordinarily diﬃcult to engineer, which
has complicated the construction of mammalian artiﬁcial
chromosomes (MACs) or human artiﬁcial chromosomes
(HACs) [27].Journal of Biomedicine and Biotechnology 3
2.1. Chromosomal Elements. All normal human centromeres
contain large arrays of alphoid satellite DNA (α-DNA), a
family of repetitive DNA sequences ﬁrst discovered in the
African green monkey [28]. Satellite DNA corresponds to
only a small fraction of the human genome (less than
2%) whereas in other species like the rat, it is much more
abundant [29]. Human α-DNA consists of tandem repeats of
a 171bp monomer arranged in highly ordered repeats [30,
31]. The divergent intermonomeric sequences lying between
the independent monomers vary from 20% to 40% whereas
the sequence divergence is around 5% in the higher order
repeats [32]. Despite this monomeric variation, each human
centromere is thought to be formed by arrays of a unique
monomer spanning from several kilobases up to megabases
[33, 34].
Several attempts to generate artiﬁcial chromosomes have
used alphoid DNA arrays from diﬀerent chromosomes (X, Y,
17, and 21), although not all have succeeded. Alphoid DNA
from chromosome Y has failed to form active centromeres
in some cases [35, 36], probably because of the lack of
CENP-B boxes [37]. Masumoto and collaborators have also
showed how two diﬀerent alphoid DNA loci from the same
chromosome behave in a completely opposite manner. They
foundthatalphoid-derivedYACunabletoformHACsdonot
have CENP-B boxes in addition to a more diverged alphoid
repeats [38].
In terms of speciﬁc DNA sequences, alphoid DNA may
not be the only element needed for centromeres to fulﬁl
their function, implicating additional mechanisms [39]. This
view is supported by the lack of a consensus sequence for α-
DNA [32], the existence of dicentric chromosomes with two
identical regions of α- D N Ab u to n l yo n ea c t i v ec e n t r o m e r e
[40–42], or the fact that functional neocentromeres can be
formed from noncentromeric DNA [43]. However, it is clear
that no DNA other than alphoid DNA can eﬃciently form
a centromere after transfection into human cells. It has been
already mention that not all alphoid DNAs can form active
centromeres with the same eﬃciency and it appears that
functional centromeres required a minimum size, estimated
to be around 100kb [44]. Lo and collaborators analysed
all chromosomes in order to determine the minimum
length of alphoid DNA tolerated by chromosomes and
still able to seed de novo centromere formation [45]. In
general, chromosomes cannot bear an important reduction
in the length of alphoid DNA array, with the exception of
chromosome 21 whose alphoid DNA could oscillate between
50 and 100kb, with an average size of 78kb.
Despite all this evidence, there are several reports where
introducingdiﬀerentarraysofalphoidDNAdoesindeedlead
to centromere formation. Several studies have shown how
when large (>50kb) arrays of alphoid DNA are transfected
into a human cell line (HT1080) in culture, de novo chromo-
somes may form with a functional centromere [35, 46, 47].
Nevertheless, much work is still needed in order to elucidate
the mechanisms underlying de novo centromere formation.
2.2. MAC Formation. There are two diﬀerent strategies to
form “de novo” HACs. The “bottom-up” approach consists
of assembling the elements needed for HAC formation
in a vector and with this aim, a universal system to
introduce alphoid DNA into any BAC [48] using in vivo
recombineering has been design, containing a 70kb array
of this alphoid DNA proven to be capable of forming de
novoMACs[38,46].Withthesecondstrategyor“top-down”
approachanexistingchromosomeismanipulatedinorderto
reduce its size, eliminating unneeded elements except for the
centromere region [49].
In the ﬁrst studies carried out on the formation of
centromeres and de novo human artiﬁcial chromosomes
(HACs) [35], synthetic alpha satellite arrays were cotrans-
fected with telomeric DNA and other genomic sequences
to obtain linear minichromosomes of 6 to 10Mb in size.
Due to the already mention sequence divergence between
alphoid DNA, arrays from 2 diﬀerent chromosomes were
usedtoobtain4minichromosomes-containingcelllines,two
with alphoid DNA from the Y chromosome and the other
two with alphoid DNA from chromosome 17. However,
three of these minichromosomes had acquired DNA from
othercentromeresorneo-centromeres,andonlyoneofthem
contained alphoid DNA exclusively from the transfected α-
DNA. The HACs were cytogenetically stable, in terms of the
presence and absence of selection, and their copy number or
size did not change over time.
Only one year later, YAC-based mammalian artiﬁcial
chromosomes (MACs) were generated [47], yeast artiﬁcial
chromosomes having been widely used to introduce mam-
malian genes into mice as they can harbour large DNA
fragments [15, 50, 51]. In these studies, a recombination
deﬁcient yeast host was used in which alphoid arrays from
chromosome 21 (α21-I and α21-II), telomere sequences and
selectable markers were introduced, and the modiﬁed YAC
was transfected into HT1080 cells. The results obtained
showedsomevariabilityregardingtheproportionofcelllines
containing minichromosomes (from 18% to 68%), although
the number of MACs per cell line was most frequently
one. The MACs obtained segregated accurately, they bound
centromeric proteins, and they were about 1–5Mb in size.
In addition, they did not gain host DNA and presented a
loss rate of less than 1% per generation in the absence of
selection.
A further advance came when it was demonstrated that
no telomere sequences are needed when the input DNA is
circular [46]. Accordingly, it was established that MACs can
be formed in HT1080 cells from either linear or circular
input DNA, with circular alphoid constructs being very
eﬀective at forming MACs, whether or not human telomere
sequences are added. Indeed, the presence of these arrays did
not favour MAC formation. By contrast, it was ascertained
how linear DNA molecules require telomere sequences to
maintain and protect minichromosome ends.
When considering the de novo formation of HACs, an
important inconvenience is the fact that these structures
are not stable in murine cell lines [52], making it diﬃcult
to perform studies in mice as a model system. When a
previously established HAC was transferred into several
murine cell lines (RAG, STO and LA-9), the HAC DNA
rearranged and was diﬀerent to the original HAC. However,
murine DNA was not acquired and no integration events4 Journal of Biomedicine and Biotechnology
were observed. When selection was withdrawn, the artiﬁcial
chromosomes were rapidly lost at a rate between 2%–5%
per day, depending on the cell line. These results show how
centromere activity is retained to some extent, as they were
stillabletobindamarkerofactivecentromere,yetaspointed
out above, they also suggested that something else is needed
to provide correct segregation.
2.3. Gene Expression from Artiﬁcial Chromosomes. The next
advance in the development of human artiﬁcial chro-
mosomes was probably the demonstration that any gene
cloned into those constructs could be expressed normally,
as addressed in several reports. There are two studies where
the entire human HPRT gene was expressed from such
mammalian artiﬁcial chromosomes (MACs) [53, 54], using
slightly diﬀerent strategies but with the same results. A PAC
containing about 140kb of genomic DNA, including the
human HPRT gene, and a second PAC including a 70kb
array of α-DNA derived from chromosome 21 (α21-I) [46]
were transfected into HPRT-deﬁcient HT1080 cells [53].
The results obtained showed how two of the three MAC-
containing cell lines generated were mitotically stable and
that HPRT expression was maintained over long periods
of time, even in the absence of selection. In a second
study, a 404kb HAC made by in vivo recombination and
introduced into HPRT-deﬁcient HT1080 cells successfully
ensured expression of the gene after two months without any
selection [55].
More recently, a 21-derived minichromosome made in
DT-40 chicken cells using the top-down approach [56]
was introduced into human HT1080 cells by microcell-
mediated chromosome transfer to check its stability [57].
Subsequently, the erythropoietin gene was added by cre-loxP
recombination and transgene expression and vector stability
was ﬁnally tested in HFL-1 cells. Accordingly, the vector
was mainly maintained as a single copy per cell with no
translocationand/orinsertionevents,andepoexpressionwas
sustained over 12 weeks without any loss in the absence of
selection.
Using the same strategy, the dystrophin gene (about
2.4Mb in length) has been cloned into a HAC [58], a
construction that enabled all the tissue-speciﬁc isoforms
of human dystrophin gene to be detected, overcoming the
problem shared by other vector systems that only produce
one of the isoforms. One year later, the same group used the
dystrophin HAC to correct patient-derived ﬁbroblasts and
then transform the corrected cells into human iPS (induced
pluripotent stem) cells [59]. This is a great achievement
as probably autologous-corrected cells would be the best
candidate cells to be used in gene therapy protocols.
2.4.Conclusions. Itseemsthatthesizeand/orstructureofthe
HAC matters since artiﬁcial chromosomes have a higher rate
of missegregation than normal chromosomes [60, 61]. It is
also notable that diﬀerent HACs behave in a diﬀerent way in
diﬀerent cell lines [62], suggesting that centromere activity
could probably be maintained by trans-acting factors with
diﬀerent speciﬁcities between diﬀerent cell lines, even within
the same species.
A better understanding of centromere function seems
crucial in order to be able to generate “synthetic” cen-
tromeres, which should improve the development of MACs.
Thus, despite some of the advances and successes, the
engineering of HACs/MACs to carry genes of interest is
evidently quite diﬃcult, which has restricted their use as
vectors for gene therapy.
3. Stable Replicating Episomes
In view of the diﬃculties associated with MACs, other
alternative vectors have been developed to carry large
genomic constructs. Among them, stable non-integrating
and replicating episomes have emerged as very promising
gene therapy vectors for dividing cells. Interestingly, these
stable episomes do not become integrated within host cell
chromosomes and are therefore not associated with any risk
of insertional mutagenesis.
3.1. OriP/EBNA-1 Vectors: Episomal Maintenance. Perhaps
the best characterized artiﬁcial minichromosome-like epi-
somes of this type are the so called OriP/EBNA1 vectors.
These vectors are bacterial plasmids or bacterial artiﬁcial
chromosomes in which episomal replication and segregation
are achieved through DNA sequences derived from the
Epstein-Barr virus (EBV). This herpes virus has a genome
consisting of dsDNA of approximately 172kb and it is
characterized by a latent phase during which it is maintained
for life asymptomatically in lymphocytes of about 90% of
the human population. In the latent stage, the viral genome
is maintained as a circular extrachromosomal replicating
episome within the nucleus of infected cells [63].
The only viral elements needed to confer replication
and segregation on this episome are the latent origin of
replication, oriP, and the viral gene encoding the EBNA1
protein [64–66]. The origin of plasmid replication (oriP)
from Epstein-Barr virus is a cis-acting element which has
been proven to confer replication autonomy and mainte-
nance to recombinant plasmids in cells harbouring latent
EBV. OriP is formed by two elements about 1kb apart: the
family of repeats (FR), a 20 member family of 30bp direct
repeats, and the dyad symmetry (DS) element, a 65bp DS
containing four copies of the repeat [67, 68]. OriP resides
withina1.8kbsegmentintheshortuniqueregionoftheEBV
genome, and it appears to be the only element needed in cis
[65, 68]. The trans-acting gene allowing oriP function lies in
a 2.6kb region encoding the Epstein-Barr Nuclear Antigen
1( E B N A - 1 )[ 66]. The EBNA-1 protein can bind to both the
FR and DS sequences [69], whereby the DS element is the
initiation site of episomal DNA replication whereas FR acts
asareplicationforkbarrierandterminationsite[70].EBNA-
1 also activates the 30bp repeats of oriPi ntrans, the latter
acting as a transcriptional enhancer for genes linked to the
repeat [71].
Plasmidscontainingthesetwoelements(oriPandEBN A -
1) are replicated once per cell cycle and they segregate
passively by attachment to the mitotic chromosomes [72,
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in tissue culture [63, 66], as well as in mouse cell lines
if the plasmid contains large fragments of genomic DNA
that permit replication [74]. Although standard EBV-derived
vectors usually carry both oriP and EBNA-1, it is well
established that vectors containing only the oriPF Ra n d
EBNA-1 as well as inserts of genomic DNA greater than
100kb can be replicated and maintained as episomes, and
c a nt h u sb eu s e df o rs t u d i e si nh u m a na n dr o d e n tc e l l s
[63]. As the segregation of episomes is passive, by binding to
endogeneous chromosomes instead of by direct attachment
to the microtubules of the mitotic spindle, selection is
sometimes required to maintain a population of cells that
carry the episomes (especially in cases of a low copy number
of episomes per cell). The typical structure of OriP/EBNA1
vectors and their localization in the interphase and mitotic
cells is shown in Figure 1.
The replication and segregation of OriP/EBNA1 vectors
depends only on the presence of EBNA-1 protein. As
mentioned above, the binding of EBNA-1 to the DS element
of OriP destabilizes nucleosomes and aids the recruitment of
cellular replication factors to OriP. The segregation function
of EBNA-1 depends on its ability to bind to both the FR
element of OriP and to the periphery of chromosomes.
It is thought that EBNA-1 interacts with chromosomes in
two diﬀerent ways. During interphase (and probably also
in mitosis), EBNA-1 associates with chromatin through its
binding to either cellular DNA or chromatin-associated
proteins. During metaphase/anaphase, there is additional
binding of EBNA-1 to a cellular protein referred to as
EBP2 (EBNA1-binding protein 2), which strengthens the
association of EBNA-1 with mitotic chromosomes [75].
3.2. Applications. OriP/EBNA-1-based vectors have been
widelyusedforavarietyofpurposes.Oneofthestrategiesfor
cloning a eukaryotic gene relies on the ability to select for the
functional expression of the gene of interest in mammalian
cells [76]. A subcloning vector has been designed containing
oriP/EBNA-1 that enables the expression of very rare clones
to be selected directly [77]. These clones were stably main-
tained asepisomes, 2to10 copies percell,aslong as selection
was applied.
Other studies using oriP/EBNA-1 vectors have expressed
cDNA from heterologous promoters, all producing high
levels of expression for several weeks or months, and all
showing stable retention of the episomes in the cells for
long periods of time [78–81]. Such vectors have even been
used to produce large amounts of recombinant proteins
[82].
There are also several studies showing how these two
elements are suﬃcient for large plasmids to be maintained
indeﬁnitely in cells, expressing the gene they contain in
a physiological fashion. For example, 2 YACs of 90 and
660kb were created that contained oriP and when they
were introduced into human cells expressing EBNA-1, these
constructs were maintained as stable episomes for more
than 8 months in the presence of selection, and for up
to 5.5 months without selection [83]. Three cell lines
were produced with the 90kb YAC, all of which contained
unrearranged episomes. However, of the 3 cell lines con-
taining the 660kb YAC only two presented the intact form
of the 660kb molecule. FISH analysis also demonstrated
how episomes, some visible as pairs, associated with the
host cell chromosomes. This association may explain how
they are so eﬃciently maintained, even in the absence of
selection, indicating that stability is achieved by attachment
to host chromosomes as proposed for the EBV genome
[84]. An intact CFTR gene has also been expressed from
an oriP/EBNA1 episome in mouse cells [85]. By introducing
circularizedYACsintoCMT-93andLA-9cellsbyfusionwith
yeast spheroplasts, nonrearranged YACs were obtained and
maintained as episomes of either 320 or 640kb. The copy
number varied between 2 to 56 in the diﬀerent cell lines
obtained and the rate of loss varied from 0.4% to 5% in the
absenceofselection,verysimilartothedatafromthe293-cell
linesexpressingoriP-YACs [83].Thelevelofexpressionofthe
exogenous CFTR gene was dependent on its copy number
and each copy of the YAC produced about 20% of the level
of each endogenous gene. A further advance was made by
changing the constructs based on YACs to others based on
BACs, as the latter are easier to use and manipulate, allowing
puriﬁcation of much larger quantities of DNA.
In order to modify BACs for their use in gene therapy
protocols, an eﬃcient system for retroﬁtting BACs with
oriP/EBNA1 and reporter genes has been described using
loxP/Cre recombination [86, 87]. These vectors not only
contain the elements needed for episomal maintenance,
they also include suitable marker genes for selection and
monitoringofthemammaliancellsintowhichtheconstructs
are introduced.
4.DeliveryMethods
As mentioned above, the type of DNA molecules used for
gene therapy is crucial but the “DNA delivery vehicles”
are also very important. Indeed, the transfer of large DNA
molecules to mammalian cells is not an easy task. Medium
size BACs can be delivered into mammalian cells using
Lipofectamine 2000, and more than half of the transfected
cells contain intact delivered BAC [87, 88]. However, when
working with BACs, the puriﬁcation of supercoiled DNA
may be quite cumbersome and it becomes increasingly
diﬃcult with larger BACs. Diﬀerent methods involving less
manipulation and/or higher eﬃciency of delivery should
be tested in order to optimize the whole system. To date,
two methods appear to be quite promising to transfer
BACs-based vectors to mammalian cells: bactofection and
packaging within Herpes simplex virus 1 (HSV-1) particles.
4.1. Bactofection. Bactofection refers to the use of bacteria
for the delivery of DNA molecules to mammalian cells. One
advantage of this method is that it minimizes the need to
manipulate the DNA molecules, which is especially useful
in the case of very large molecules such as BACs. Indeed,
diﬀe r e n ts t u d i e sh a v ep r o v e nh o wD N At r a n s f e rc a no c c u r
from bacteria to mammalian cells [89–91]. Hence, bacterial
strains that are naturally or artiﬁcially engineered to be
invasive, but that are attenuated to prevent pathogenesis, are6 Journal of Biomedicine and Biotechnology
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Figure 1: (a) Structure of oriP/EBNA-1 vectors. The scheme represents a frataxin expression plasmid-containing episomal elements
(oriP/EBNA-1). (b) orP/EBNA-1 plasmids remain as stable replicating, nonintegrating episomes within nuclei of interphase (and
postmitotic)cells.(c)oriP/EBNA-1episomesattachtotheperipheryofchromosomesthroughEBNA-1proteinandsegregateduringmitosis.
particularly useful for bactofection. Accordingly, attenuated
intracellular bacteria engineered to lyse after cell invasion
have been shown to transfer functional genes to a very
broad range of mammalian cells [92, 93]. The main bacterial
species used as delivery vectors are facultative intracellular
pathogens such as Salmonella sp [94], Shigella sp [95],
Listeria sp [96], or Yersinia sp [97]. However, more recently,
it was demonstrated that almost any species can be used
provided they are appropriately engineered [98]. Anaerobic
or facultative anaerobic bacteria are also being applied as
anticancer agents to target solid tumours taking advantage
of their ability to grow in the hypoxic region of tumours
[96,98–103].Indeed,bacterialdeliveryhasbeenassessedasa
way to administer DNA vaccines using diﬀerent intracellular
pathogen strains [104, 105]. For certain purposes, deter-
mined bacterial toxins have been used as vectors to deliver
DNA into mammalian cells [106].
Ad i ﬀerent approach for bacterial delivery relies on the
use of a genetically modiﬁed E. coli strains that express
two additional genes; inv from Yersinia pseudotuberculosis,
and hly from Lysteria monocytogenes [107, 108]. Inv permits
binding to the integrins expressed on the surface of mam-
malian cells and hly, the escape from lysosomes once in the
cytosol of the mammalian cells. E. coli is also auxotrophic for
aminopimelic acid (DAP−), which means that it is not able
to form a new cellular membrane once in the mammalian
cytosol. For this reason it lyses and freely liberates the
DNA it contains. The Y. pseudotuberculosis invasin protein
(inv) is encoded by a 3.8kb gene expressing a 103kDa
protein localized to the outer membrane, part of a family
of adhesins encoded by enteropathogenic bacteria [109]. All
the members of this family have a region of similarity in the
amino terminal 500 amino acids of the Y. pseudotuberculosis
invasin (36% identity). This conserved domain is required
for protein localization in the outer membrane and for
export of the carboxyl termini of these proteins. Indeed,
the terminal 192 amino acids of invasins represents the
most divergent region and it is that which binds to integrin
receptors [110, 111]. Invasin is the only protein needed to
invade mammalian cells and it can be cloned into non-
invasive strains of bacteria making them invasive [89, 112].
The second gene introduced in the modiﬁed E. coli strain is
thehly locusfromL.monocytogenes,encodinglisteriolysinO.
This protein is a member of the cytolysin family that are pro-
duced by various Gram positive species [113]. This 58kDa
cholesterol-dependent pore-forming toxin [114] allows the
bacteria to escape from phagolysosomes into the cytosol
of the infected cell [115]. In order to promote lysis of the
internalized bacteria, the strain used is unable to synthesise
a new cell wall when it divides since it is a diaminopimelic
acid (dap) auxotrophic strain, a substrate not present in
the mammalian cells. This ensures that the bacteria will
not survive in the cells, and that the plasmid DNA will be
liberated into the cytosol and eventually reach the nucleus.
Using this bacterial vehicle, functional DNA can be
transferred into a variety of mammalian cell lines by
simple coincubation with the engineered E. coli strain [107].
Diﬀerent studies have showed that this strain is also able
to transfer large DNA fragments [116–118], establishing the
proof-of-principle for the use of this kind of delivery method
as a true alternative to eﬃciently deliver intact BACs into
recipient mammalian cells.
Currently, the use of bactofection seems to be limited
to ex vivo gene transfer to cultured mammalian cells,
although some examples of in vivo applications to cells
of the gastrointestinal tract are envisaged. However, there
are very serious concerns about the biosafety of bacteria
as gene delivery vehicles due to the risks of important
adverse immunological and inﬂammatory reactions, which
will probably restrict their wider application in gene therapy.
4.2. Packaging into HSV-1 Virions. Vectors based on Herpes
simplex virus 1 (HSV-1) represent one of the most promising
alternatives for the delivery of large DNA molecules, includ-
ing many artiﬁcial minichromosome-like episomes. HSV-1
has a genome of 152kb, so viral vectors based on HSV-1
have a notably larger capacity to accommodate DNA than
other conventional viral vectors used for gene therapy, such
as retroviruses and adenoviruses [119].
HSV-1 derived amplicon vectors are plasmids (or BACs)
bearing only two sequences of viral origin: an OriS to permitJournal of Biomedicine and Biotechnology 7
replication in packaging cells; and a pac sequence to permit
packaging into HSV-1 viral particles. Hence, the remaining
genomic capacity is available for exogenous DNA (up to
approximately 150kb), which may include entire genomic
loci with all their regulatory elements to ensure persistent
and physiologically regulated levels of expression [120–123].
This feature is probably the most promising characteristic
of this type of vector as, to date, they are the only viral
vectors with such a characteristic high eﬃciency of gene
transduction that are capable of carrying such large DNA
fragments that they may include a whole genomic locus.
Other relevant aspects of HSV-1 amplicons as gene delivery
vehicles include their capability to transduce both dividing
and non-dividing cells, and their ability to persist as non-
integrating episomes, eliminating the risk of insertional
mutagenesis.
As amplicon vectors only contain the oriS and the pac
packaging signal as viral DNA sequences, generating them
requires the use of a helper virus encoding all the viral genes
necessary for the assembly and packaging of DNA into viral
particles. This helper virus, although replication-defective,
quite often produces amplicons contaminated with helper
virusesthatcantriggerimmuneandinﬂammatoryresponses
[124]. Recently, a new system has been developed where all
the genes needed for packaging are encoded in a large BAC
(which is unable to be packed within virions), eliminating all
the genes unnecessary to generate the amplicon-containing
particles [123, 125, 126].
HSV-1 amplicons can play an important role in gene
therapy protocols for neurological disorders due to their
notable ability to deliver genes into neurons, both in vitro
and in vivo [127–131]. Although they can express foreign
genes driven by viral promoters only for a period of several
days, genes under the control of a neuronal promoter can
be stably expressed [132] .I nt h i sc o n t e x t ,i ti sn o ts u r p r i s i n g
that expression from a genomic locus where the gene is under
the control of its own promoter renders physiological levels
of expression that are maintained stably [121]. As neurons
are postmitotic cells, there is no need for reinoculation of the
therapeuticgeneshouldagenetherapyprotocolusethiskind
of vector. However, for dividing cells some modiﬁcations
w o u l dh a v et ob em a d et ot h ea m p l i c o nv e c t o r si no r d e r
for them to persist during cell divisions. One approach is to
use hybrid amplicons containing elements from HSV-1 and
elements from the Epstein-Barr virus that confer episomal
retention [121, 122].
Figure 2 shows the structure of an HSV-1-derived ampli-
con vector encompassing an EBV-based minichromosome-
like episome, and the procedure to pack it into HSV-
1 virions. Given the high capacity of these vectors, even
artiﬁcial minichromosomes may be delivered to mammalian
cells with an eﬃciency higher than that obtained by other
methods [133]. Thus, HSV-1 HAC amplicons containing
alphoid DNA for episomal maintenance and a HPRT mini-
gene have eﬃciently transduced cultured cells, producing
stable HPRT expression for over three months. Curiously,
notallHACsbehaveinthesamewayinthediﬀerentcelllines
tested, which was probably due to the level of expression of
some proteins implicated in cell cycle control [133].
Whereas HSV-1 virions are unable to pack DNA
molecules larger than 160kb, viral vectors based on other
herpes viruses may have a greater capacity to accommodate
exogenous DNA. Thus, cytomegalovirus, which has a 250kb
genome, may permit larger DNA fragments to be used [134].
In this way, herpes virus-based vectors appear to be highly
promising “delivery vehicles” of artiﬁcial minichromosome-
like episomes for gene therapy applications.
4.3. Gene Therapy of Haemophilia A. Haemophilia A is an
X-linked recessive bleeding disorder caused by mutations
in the Factor VIII gene (FVIII) that encodes for a clotting
factor [135]. It aﬀects about 1 in 5,000 male births in all
populations and it is currently treated by infusion of plasma-
derived or recombinant Factor VIII protein. The frequency
of the disorder combined with the high cost of recombinant
Factor VIII make it a major burden on the healthcare
systems. Therefore, gene therapy for FVIII deﬁciency is
clearly a very attractive option. There are diﬀerent degrees
of severity for this disease depending on the levels of the
circulating-factors (severe, less than 1%; moderate, between
2%–5%; and mild, between 6%–30%), Thus, low levels of
expression may have a large positive eﬀect on the health of
the individual. Interestingly, FVIII is normally expressed in
the liver, an organ that is particularly easy to access for gene
delivery. Much work has been carried out towards preparing
gene therapies for both FVIII (haemophilia A) and Factor
IX (FIX) deﬁciencies (hemophilia B). FIX is a much smaller
protein encoded by a 1385bp open reading frame that can
be easily packaged as a minigene in retroviral, adenoviral
and adeno-associated (AAV) vectors driven by either a viral
or a mammalian promoter [136–139]. Long-term delivery
and physiological expression have been achieved for FIX in
mouse models, although many problems remain and gene
therapy suitable for human patients is still not available
[135].Bycontrast,theopenreadingframeofFVIIIis7055bp
long and it has been much harder to express in viral vectors
[140]. Diﬀerent strategies have been applied to make the
FVIII cDNA a bit shorter, and hence easier to introduce into
diﬀerent vectors,including using a B-domain deleted version
of FVIII cDNA [141, 142] as this domain does not appear to
be essential for coagulation [14, 143–145].
In view of these data, it seems that the election of the
vector into which the FVIII gene has to be introduced is
not a minor issue for haemophilia A gene therapy. First
generation adenovirus-based vectors still contained viral
gene sequences that produced immunogenic reactions and
as a consequence, transgene expression was only short-lived
as a result of vector clearance [146]. Nevertheless, even with
these vectors it might be possible to achieve curative levels
of FVIII for several months in haemophilic mice [147, 148].
However, the results from larger animals were not so
promising [149, 150] and although some improvements in
adenoviral vectors have been made, particularly regarding
transgene expression, some toxicity still persists when these
vectors are used [151, 152].
There is evidence of the expression of the FVIII cDNA
with the B-domain deleted from retroviral vectors in dif-
ferent cells lines, from human skin ﬁbroblasts [153, 154]t o8 Journal of Biomedicine and Biotechnology
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Figure 2:PackagingofOriP/EBNA-1episomesintoherpesviralparticles.HSV-1BACandICP27plasmidaretheelementsusedforpackaging
herpesvirus using the helper-free system.
bone marrow stromal cells [155]. In each case, a functional
FVIII factor is expressed but at low levels, due to the
repressive sequences found in the cDNA of FVIII gene
[156–159]. However, this diﬃculty has been overcome by
using slightly diﬀerent retroviral vectors based on the MFG
retroviral vector system [160]. Yet, in these systems, the
therapeutic levels of FVIII in circulation were obtained over
just one week [161]. An important drawback of retroviral
vectors is their inability to transduce nondividing cells,
particularly important if gene therapy is directed to the
liver. One way to bypass this limitation has been to use
FVIII-expressing retroviral vectors to transduce neonatal
mice where hepatocytes are undergoing rapid cell division,
thereby obtaining complete correction of the disease [162].
Ad i ﬀerent approach is to employ lentivirus-based vectors
which can transduce both dividing and non-dividing cells
[163, 164].
Due to the small genome of adeno-associated virus
(AAV) vectors, they have been used little with theFVIII gene.
Nonetheless, there are reports of therapeutic levels of FVIII
expression for a limited period of time using this viral system
[165, 166]. Perhaps due to the disappointing results obtained
with other viral vectors, delivery systems based on AAV
vectors have recently attracted signiﬁcant attention [167].
Besides the limitations presented by viral delivery sys-
tems, three phase I trials have been launched to test the
safety of the procedure and to check the levels of expression
from these vectors. In an ex vivo gene therapy protocol, a
B-domain deleted FVIII cDNA expressed from a non-viral
plasmid was electroporated into dermal ﬁbroblasts and, after
selection and expansion, the ﬁbroblasts were reintroduced
into the patients [168]. FVIII levels increased in four of
the six subjects studied without producing adverse events.
In the patient with the highest levels of FVIII expression,
the therapeutic eﬀects lasted for 10 months, although
FVIII expression ﬁnally disappeared. In a second trial, a
B-domain-deleted cDNA was expressed from a moloney
murine leukaemia virus-based (retroviral) vector [169],
which only produced levels of FVIII expression above 1%
sporadically,concludingthateﬃcientretroviraltransduction
would probably require higher doses and some degree of
mitotic induction. In 2004, a third trial using an adenovirus
vector encoding the complete FVIII cDNA was carried out in
just a single patient. Despite obtaining sustained expression
of FVIII above 1% of the normal levels for several months,
adverse eﬀects were observed associated with the appearance
of thrombocytopenia and an elevation of transaminases
[170].
There is only one study where factor VIII has been
expressed from a BAC containing the entire genomic locus
[118]. As no single FVIII-containing BAC was available,
a new one was constructed by homologous recombina-
tion [171] and then retroﬁtted with diﬀerent elements
in order to provide episomal maintenance [48, 88]. The
diﬀerent vectors obtained were introduced into hepatic
and nonhepatic human cell lines to check whether the
construct could drive expression from the transgene, achiev-
ing detectable FVIII levels with all of them and in someJournal of Biomedicine and Biotechnology 9
cases, even stronger expression than the endogenous gene.
Although a demonstration of functional FVIII expres-
sion from the BAC awaits the use of cell lines or mice
with null endogenous expression, this is the ﬁrst char-
acterized genomic clone carrying the intact locus which
could potentially be useful for therapeutic applications
[118].
4.4. Gene Therapy for Friedreich’s Ataxia. Friedreich’s ataxia
(FA) is the most common form of autosomal recessive ataxia
and it is caused by a decrease in the levels of frataxin, a
mitochondrial protein encoded by the nuclear FRDA (FXN)
gene [172]. FA is a predominantly neurodegenerative disease
with an estimated prevalence of 1-2 in 50,000 individuals,
and it is characterized by the progressive loss of large
sensory neurons and spinocerebellar tracts. Other clinical
symptoms may include hypertrophic cardiomyopathy and
diabetes mellitus.
The most common cause of the disease is an expansion
of the GAA triplet within the ﬁrst intron of the FRDA
gene, which has a dramatic eﬀect in reducing mRNA levels
and consequently frataxin protein levels [173]. Although
most patients have both chromosomes aﬀected by the
GAA expansion, it is possible to ﬁnd some cases with
one expanded allele and a point mutation in the other
[174].
Frataxin is an 18KDa protein [175] implicated in
functions such as mitochondrial iron homeostasis [176,
177], iron-sulfur cluster biosynthesis [178] and oxidative
phosphorylation [179]. Frataxin is expressed in all cell types,
although cells from the nervous system, heart and muscle
present the highest levels of the protein [180].
Homozygous frda knockout mice are embryonic lethal
a few days after implantation, demonstrating the essential
role for frataxin during early mammalian embryo devel-
opment [181]. Thus, it appears that the milder pheno-
type associated with the human disease is due to the
residual frataxin expression observed in patients with the
expansion mutations. These results may also explain why
no patients with homozygous point mutations have been
encountered.
It has been diﬃcult to generate mouse models for
FA because of the embryonic lethality associated with the
null mutations. Neuron-speciﬁc and conditional knock-out
models generally exhibit a wider and more prominent
neurodegenerative phenotype than the human disease [182,
183]. Some knock-in mice bearing the human gene with an
expansion mutation surprisingly failed to develop any clin-
ical phenotype, despite the signiﬁcant reduction in frataxin
levels to 25%–36% the wild-type levels [184]. More recently,
r e p r e s e n t a t i v eF Am o u s em o d e l sh a v eb e e ng e n e r a t e db y
crossbreeding lines of a human FXN YAC transgenic mice
that contain unstable GAA repeat expansions with heterozy-
gous frda knock-out mice [185]. The resultant “transgenic-
knockout” mice express comparatively little human-derived
frataxin, and they exhibit a neurodegenerative and cardiac
pathological phenotype similar to human disease suﬀerers,
although signiﬁcantly milder. With their limitations, these
mice currently constitute the most useful model to study the
physiopathology of FA and to test for possible therapeutic
approaches.
There is no eﬀective cure for FA, although antioxidants
may have a mildly positive eﬀect on some clinical signs
[186]. There has been great interest in the possibility of
boosting frataxin gene expression as a therapeutic approach
and indeed, erythropoietin [187] has been shown to increase
frataxin protein levels in cultured cells from FA patients. In
a pilot clinical trial, 12 patients were treated with human
recombinant erythropoietin (rHeEPO) to establish whether
it could produce an increment in frataxin levels [188]. After
8 weeks of treatment, only two patients experienced a net
increment in frataxin levels in peripheral blood lympho-
cytes, patients who also showed a reduction in markers of
oxidative stress. However, it is not yet clear whether or not
erythropoietin raises frataxin levels within aﬀected neurons.
Since chromatin condensation around the GAA repeat is
thought to be responsible, to some extent, for the low levels
of frataxin mRNA expression in FA, histone deacetylase
(HDAC) inhibitors have also been investigated with the same
encouraging results [189, 190].
FA is a good candidate for treatment with gene therapy
as it is a monogenic disease and an increases in frataxin
level could substantially improved the symptoms given that
healthy carriers may have around 40%–50% of normal
frataxin levels [191].
A human frataxin cDNA has been delivered into FA
patient ﬁbroblasts using lentiviral or adeno-associated viral
(AAV) vectors, which has resulted in a partial correction
of their sensitivity to oxidant stress [192]. However, the
nonphysiological overexpression of frataxin driven by these
vectors has been shown to be cytopathological.
Interestingly, the expression of frataxin cDNA to “phys-
iological” levels driven by a HSV-1 amplicon vector can
rescuetheneurodegenerationtriggeredbyfrataxindeﬁciency
both in cultured neurons and in vivo [193]. These results
constitute the ﬁrst “proof of principle” that neurological
function can be recovered through a gene therapy approach
aimed at correcting frataxin deﬁciency.
As mentioned above, it seems that optimal frataxin
levels are required for correct cell function, since both
deﬁciency and massive overexpression are associated with
cell pathology. Thus, physiologically regulated expression of
frataxin gene seems to be important for the gene therapy
to succeed in FA. An interesting possibility is the use of
the entire genomic locus of frataxin, since its large size may
ensure the inclusion of all the regulatory elements required
for proper gene expression.
Previous reports of transgenic mice indeed support
the use of the frataxin genomic locus to correct frataxin
deﬁciencyinvivo.Thus,theentireFXNgenewithinahuman
YAC clone of 370kb was reported to rescue the embryonic
lethality of frataxin knock-out mice [19]. Likewise, a human
BAC clone of 188kb containing the entire genomic FXN
locus has also been demonstrated to rescue the lethal
phenotype of frataxin deﬁciency [16]. This indicates that
the FRDA-BAC contains all the regulatory elements needed
for the FRDA gene to be expressed in a physiological
fashion.10 Journal of Biomedicine and Biotechnology
A slightly smaller FRDA-BAC of 135kb containing the
entire 80kb FXN genomic locus has been used to generate
an HSV-1 amplicon (iBAC-FRDA) in order to test its ability
to correct the FA phenotype [194]. This vector is capable of
restoring physiological levels of frataxin in ﬁbroblasts from
FA patients and hence, of almost completely rescuing the
cell phenotype of susceptibility to oxidative stress. Another
key issue when using this kind of vector is the ability to
infect cells that are hard to transfect with other techniques
[195]. Once FRDA expression from the iBAC has been
demonstrated, the iBAC might be used for in vivo delivery of
the FRDA gene to FA-aﬀected regions since delivery of HSV-
1 amplicons to determined brain regions has already been
shown [127]. Indeed, we have results indicating that HSV-
1 amplicons containing the entire frataxin genomic locus
produce persistent gene expression in the nervous system
in vivo (Corona et al., manuscript in preparation). All these
results support the promise of these vectors for gene therapy
of FA.
In this regard, it is particularly interesting that herpes
viral vectors are now in clinical trials for gene therapy of
chronic pain. The results of this trial will provide the ﬁrst
clues about the safety and eﬃcacy of herpes viral vectors
as “gene-delivery vehicles” in the human nervous system
[196].
5. Conclusions
Artiﬁcial chromosomes and minichromosome-like episomes
based on BACs containing entire genomic loci are very
promising tools for gene therapy of inherited diseases caused
by recessive mutations, such as haemophilia or Friedreich’s
ataxia. The development of vehicles capable of accommodate
whole genes emerges like a priority due to the importance of
correct and accurate expression of most genes. Even if this
is the key question, we should not forget that the way these
molecules are delivered into target cells is as important as
the former. So, improved development of delivery methods
should be as well crucial for the success of gene therapy
using these large DNA molecules. In this respect, amplicon
vectors based on herpes viruses are currently a very useful
tool regarding average BACs but still much work is needed
in order to increase their DNA capacity or ﬁnding alternative
methods for delivery.
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